

10/585448

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

1AP20Rec'd PCT/PTO 07 JUL 2006

Applicant: Paul Adriaan VAN DER SCHAAF et al.

Title: CRYSTALLINE FORMS OF RIZATRIPTAN BENZOATE

Appl. No.: Not Assigned

Filing Date: July 7, 2006

Examiner: Not Assigned

Art Unit: Not Assigned

Atty Docket No: LNK-016

MAIL STOP AMENDMENT

Honorable Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached form PTO-1449. It is respectfully requested that the documents be expressly considered during the prosecution of this application, and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. Accordingly, no certification or fee is required.

The documents listed on the Form PTO-1449 attached hereto were cited during prosecution of the international phase of the instant application (PCT/EP05/000034).

In accordance with 37 C.F.R. §§ 1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search had been made or that information cited is, or is

10/585448

National Phase Entry for PCT/EP05/000034

Atty Docket No.: LNK-016

SAP20Rec'd USPTO 07 JUL 2006

considered to be, material to patentability as defined in 37 C.F.R. § 1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item, and Applicant reserves the right to prove that the date of publication is in fact different.

The Commissioner is authorized to charge any deficiency in any fees pursuant to 37 CFR § 1.17 associated with this communication and to credit any excess payment to Deposit Account No. 50-2101.

Respectfully submitted,

Date: 07/07/06

By: Chalin A. Smith

SMITH PATENT CONSULTING, LLC
P.O. Box 2726
Alexandria, VA 22301

Tel: 703-549-7691
Fax: 703-549-7692

Name: Chalin A. Smith
Title: Attorney for Applicant
Registration No. 41,569

CUSTOMER NUMBER 31,496

SHEET 1 OF 1

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)				ATTY. DOCKET NO. LNK-016	SERIAL NO. 107229448 Not Assigned	
				APPLICANT Paul Adriaan VAN DER SCHAAF et al.		
				NATIONAL PHASE FILING DATE July 7, 2006	GROUP Not Assigned	
U.S. PATENT DOCUMENTS						
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE
/SY/ (A)	5,567,824	10/22/1996	Chen et al.	--	--	
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY/APPLICANT	CLASS	SUBCLASS	Translation Yes No
/SY/ (B)	EP 0 497 512 A2	08/05/1992	Merck Sharp & Dohme Ltd (Europe)	--	--	
/SY/ (C)	GB 2,315,673	02/11/1998	Merck & Co. Inc. (UK)	--	--	
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)						
/SY/ (D)	Written Opinion of the International Searching Authority issued in PCT/EP05/000034 (2005)					

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

/Shawquia Young/

07/16/2009